Monassier J P, Hanssen M
Service de Cardiologie, Clinique Saint-Joseph, Colmar.
Drugs. 1987;33 Suppl 3:282-5. doi: 10.2165/00003495-198700333-00053.
86 patients with a first myocardial infarction presenting within 6 hours of the onset of symptoms were randomly allocated to treatment with intravenous streptokinase or anisoylated plasminogen streptokinase activator complex (APSAC). Side effects were observed in 34.1% of patients (15 of 44) in the streptokinase group and 23.8% (10 of 42) in the APSAC group. These effects included injection related effects (in 4 patients on streptokinase versus 6 on APSAC) and neurological complications (0 vs 2 patients, respectively). Femoral haematoma accounted for the majority of bleeding events. Death occurred as a consequence of haemorrhage in 2 patients (1 receiving streptokinase and the other APSAC).
86例在症状发作6小时内首次发生心肌梗死的患者被随机分配接受静脉注射链激酶或茴香酰化纤溶酶原链激酶激活剂复合物（APSAC）治疗。链激酶组34.1%（44例中的15例）的患者和APSAC组23.8%（42例中的10例）的患者出现了副作用。这些副作用包括注射相关反应（链激酶组4例，APSAC组6例）和神经并发症（分别为0例和2例）。股部血肿是出血事件的主要原因。2例患者因出血死亡（1例接受链激酶治疗，另1例接受APSAC治疗）。
